Metabolomic analysis identifies potential diagnostic biomarkers for aspirin‐exacerbated respiratory disease. Issue 1 (27th September 2016)

• Record Type: Journal Article
• Authors: Ban, G.‐Y.; Cho, K.; Kim, S.‐H.; Yoon, M. K.; Kim, J.‐H.; Lee, H. Y.; Shin, Y. S.; Ye, Y.‐M.; Cho, J.‐Y.; Park, H.‐S.
• Is Part Of: Clinical & experimental allergy. Volume 47:Issue 1(2017)
• Page Start: 37
• Page End: 47
• Publication Date: 2016-09-27
• Subjects: aspirin‐exacerbated respiratory disease -- biomarker -- serum LTE4; Allergy -- Periodicals; Immunology -- Periodicals; 616.97
• DOI: 10.1111/cea.12797
• Languages: English
• ISSNs: 0954-7894

Abstract

Summary: Background: To date, there has been no reliable in vitro test to diagnose aspirin‐exacerbated respiratory disease (AERD). Objective: To investigate potential diagnostic biomarkers for AERD using metabolomic analysis. Methods: An untargeted profile of serum from asthmatics in the first cohort (group 1) comprising 45 AERD, 44 patients with aspirin‐tolerant asthma (ATA), and 28 normal controls was developed using the ultra‐high‐performance liquid chromatography (UHPLC)/Q‐ToF MS system. Metabolites that discriminate AERD from ATA were quantified in both serum and urine, which were collected before (baseline) and after the lysine‐aspirin bronchoprovocation test (Lys‐ASA BPT). The serum metabolites were validated in the second cohort (group 2) comprising 50 patients with AERD and 50 patients with ATA. Results: A clear discrimination of metabolomes was found between patients with AERD and ATA. In group 1, serum levels of LTE4 and LTE4 /PGF2 α ratio before and after the Lys‐ASA BPT were significantly higher in patients with AERD than in patients with ATA ( P < 0.05 for each), and urine baseline levels of these two metabolites were significantly higher in patients with AERD. Significant differences of serum metabolite levels between patients with AERD and ATA were replicated in group 2 ( P < 0.05 for each). Moreover, serum baseline levels of LTE4 and LTE4 /PGF2 α ratio discriminated AERD from ATA with 70.5%/71.6% sensitivity and 41.5%/62.8% specificity, respectively (AUC = 0.649 and 0.732, respectively P < 0.001 for each). Urine baseline LTE4 levels were significantly correlated with the fall in FEV1 % after the Lys‐ASA BPT in patients with AERD ( P = 0.008, r = 0.463). Conclusions and Clinical Relevance: Serum metabolite level of LTE4 and LTE4 /PGF2 α ratio was identified as potential in vitro diagnostic biomarkers for AERD using the UHPLC/Q‐ToF MS system, which were closely associated with major pathogenetic mechanisms underlying AERD.